Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 901–1,000 of 1,001
Noback, M. N., Kenton, J. A., Klein, A. K., Hughes, Z. A., Kruegel, A. C., Schmid, Y., Halberstadt, A. L., & Young, J. W. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110334 · Cited by 3
Enhanced independence: De-biasing processes in psychedelic research and beyond
Cheung, K., Ehrenkranz, R. C., & Yaden, D. B. (2025) · Research Ethics · doi:10.1177/17470161251326588 · Cited by 3
“The re-emerging field of psychedelic 1 research has conducted numerous RCTs testing if various psychedelic compounds can improve symptoms of mental disorders including depression and anxiety (e.g. Raison et al., 2023; Goodwin et al., 2022; Carhart-Harris et al., 2021; Griffiths et al., 2016).”
McCoy, K., Reed, F. M., Conn, K., & Foldi, C. J. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.114957 · Cited by 4
“The major benefits of psilocybin compared to current medications are that it is rapid-acting, does not require daily administration, and is considered to be relatively safe and well-tolerated [20,50].”
The role of self-transcendent emotions in psychedelic experiences: a two-process proposal
Cova, F., & Seragnoli, F. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2526652 · Cited by 3
“…have seen renewed interest in the therapeutic potential of psychedelic substances, such as LSD and psilocybin, and entactogenic substances, such as MDMA, to treat mental disorders (Nutt, 2019) like mood disorders (R. Carhart-Harris et al., 2021) and addictive disorders (Bogenschutz et al., 2022).”
Modification of natural tryptamines for the treatment of neuropsychiatric diseases
Palfreyman, M. G., Varty, G. B., Stang, E. M., Boltaev, U., Avery, K., & Nivorozhkin, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368362 · Cited by 3
“Finally, we will review the latest developments on understanding the pharmacology and post-receptor binding events that could be underlying these potentially field changing therapies. treatment of major depressive disorder (MDD) (Davis et al., 2021; Raison et al., 2023), treatment resistant depression (TRD) (Carhart-H…”
InfluentialEducational Materials and Image Induction Increase Treatment Credibility
Low, F., & Earleywine, M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2154722 · Cited by 3
“A comparison of PAT and the antidepressant escitalo-pram found comparable changes in patient improvement (Carhart-Harris et al. 2021).”
ResultJones, G. M., Lipson, J., & Wang, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-29763-x · Cited by 4
Silva, J., Garcia, J., Guimarães, R., Palito, C., Lemos, A. M., Barros, L., & Alves, M. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-18587-8_16 · Cited by 5
Rhythms of Recovery: Integrative Medicine for PTSD and Complex Trauma
Korn, L. E. (2023) · Routledge eBooks · doi:10.4324/9781003231455 · Cited by 4
Psychedelika in der Psychiatrie: Einführung und Stand klinischer Studien
Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2233-4301 · Cited by 3
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
“The second is that these psychoactive drugs modify how context and internalized information, including memories, over a six-week time period to a similar extent as daily repeated escitalopram, a selective serotonin reuptake inhibitor (SSRI) that is an established treatment for depression (40).”
BackgroundEngel, L. B., Thal, S. B., Bright, S. J., & Low, M. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00377 · Cited by 3
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need
de Jonge, D., van der Meer, P. B., Kramers, C., & Schellekens, A. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01567-4 · Cited by 3
“However, secondary outcomes such as remission (at 6 weeks: 57% in psilocybin group vs. 28% in escitalopram group) generally favoured psilocybin over escitalopram [52].”
Cuttler, C., Stueber, A., Simone, J. J., & Mayo, L. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2452226 · Cited by 3
“Since then, studies have explored the use of psilocybin or MDMA-assisted psychotherapy across a range of disorders including depression (Carhart-Harris et al. 2016, 2021; Davis et al. 2020; Goodwin et al. 2023; von Rotz et al. 2023), posttraumatic stress disorder (PTSD) (Mitchell et al. 2021, 2023;…”
Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
Kruger, D. J., Albrecht, J., Aday, J. S., Barron, J., Herberholz, M., & Boehnke, K. F. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2461999 · Cited by 4
“In recent years, clinical trials combining psychedelics with therapy have demonstrated promise for a wide variety of psychiatric conditions (Bogenschutz et al. 2022; Carhart-Harris et al. 2021; Johnson et al. 2014; Mitchell et al. 2021).”
Hooper, J., Williams, S. L., Mueller, R. L., & Hutchison, K. E. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2727016 · Cited by 4
Earleywine, M., Low, F., & Leo, J. A. D. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00187 · Cited by 3
Reasoning about Death in Biomedical Decision-Making
Weissman, J. (2022) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/jhac009 · Cited by 3
The Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
Young, A. H. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211070065 · Cited by 3
“Carhart-Harris et al. (2021b) ask if pragmatic research, realworld data and digital technologies can aid the development of psychedelic medicine.”
BackgroundClassical Hallucinogens As Antidepressant Drugs: A Cautionary Approach
SANTOS, R. G. D., Rossi, G. N., Hallak, J. E. C., Öngür, D., & Dursun, S. M. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220425133824 · Cited by 3
“The authors noted that larger and longer trials comparing psilocybin with established antidepressants are required [11].”
BackgroundMethodOrlowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/k4xfg
Classic psychedelics: past uses, present trends, future possibilitiesPreprint
Safron, A., & Johnson, M. W. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/eys2j · Cited by 6
González-Rodriguez, D., & Perez-Carmona, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9rnj8 · Cited by 3
Gordon, A. R., Carrithers, B. M., Pagni, B. A., Kettner, H., Marrocu, A., Nayak, S. M., Weiss, B., Carhart-Harris, R. L., Roberts, D. E., & Zeifman, R. J. (2024) · Research Square · doi:10.21203/rs.3.rs-4203641/v1 · Cited by 5
Self-citationNeuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics
Wall, M. B., Harding, R., Ertl, N., Barba, T., Zafar, R. R., Sweeney, M., Nutt, D. J., Rabiner, E. A., & Erritzøe, D. (2024) · Neuroscience Insights · doi:10.1177/26331055241286518 · Cited by 3
Self-citationWITHDRAWNPreprint
Szigeti, B. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/vhs4a_v1 · Cited by 3
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 3
Self-citationFrom psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
The way of O: phenomenology of psychedelic use and the path to ultimate reality
Miller, C. W. T. (2024) · Psychodynamic Practice · doi:10.1080/14753634.2024.2371787 · Cited by 3
“…et al., 2014; Johnson et al., 2014; Tap, 2024), depression and anxiety (including in individuals with serious and terminal medical conditions) (Carhart-Harris et al., 2021; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016; Sanches et al., 2016), obsessive-compulsive disorder (OCD)…”
Bezo, A., Roméo, B., Strat, Y. L., Strika-Bruneau, L., Benyamina, A., & Hermand, M. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424263 · Cited by 2
“…who believed in effectiveness of psychedelics mentioning psychiatry and oncology as areas of potential treatment, specialties that are thoroughly studied in publications (Carhart-Harris et al. 2016, 2021; Griffiths et al. 2016; Palhano-Fontes et al. 2019; Romeo et al. 2020; Ross et al. 2016).”
Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans
Mills, E., Thurston, L., Yang, L. Y., Hunjan, T., Phylactou, M., Patel, B., Clarke, S. A., Izzi‐Engbeaya, C. N., Tsoutsouki, J., Young, M., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf128 · Cited by 2
Factors associated with suicidal ideation in drug-naïve patients with major depressive disorder
Liu, X., Liu, Y., Gao, Y., Zhang, C., Zhou, C., Li, S., Li, M., & Li, J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.111 · Cited by 2
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0039 · Cited by 3
“18 Carhart-Harris et al. (2021) conducted an RCT and randomized patients ( n = 59) with MDD to two separate doses of 25 mg psilocybin 3 weeks apart plus 6 weeks of daily placebo or two separate doses of 1 mg psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram.”
Aicher, H., Wicki, I. A., Meling, D., Mueller, M. J., Dornbierer, D., & Scheidegger, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251344689 · Cited by 3
“The recent resurgence of psychedelic research (Tullis, 2021) has brought forth promising results in the treatment of mood and anxiety disorders (Carhart-Harris et al., 2016, 2021; Gasser et al., 2015; Gukasyan et al., 2022; von Rotz et al., 2023).”
Palmisano, V. F., Agnorelli, C., Faraji, S., & Nogueira, J. J. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01252j · Cited by 2
Fearful symmetry in altered states: a bi-logic account of psychedelic action
Goldreich, M. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1632923 · Cited by 2
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Bilenker, D., & Avena, N. M. (2025) · Brain Sciences · doi:10.3390/brainsci15080893 · Cited by 2
“There is encouraging preclinical evidence in neurological disorders including Alzheimer’s dementia [114] and Parkinson’s disease [115], and clinical evidence emerging in non-eating disorder psychiatric illnesses, namely depression [116], OCD [117] and addiction [118].”
Beaussant, Y., Oglesby, C., Roddy, K., Sanders, J. J., & Agrawal, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00460 · Cited by 3
Li, R., Yan, H., Chen, Y., Liu, Y., Tang, L., Yu, J., Liu, J., Wang, H., Wang, S., & Cheng, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02045 · Cited by 3
Jungwirth, J., Westenhöfer, S., Aicher, H., Provaznikova, B., Kronenberg, G., Seifritz, E., Prinz, S., & Olbrich, S. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101719 · Cited by 2
“16,30,31 However, they fell within the lower range of recent larger RCTs with response rates of 37–42%, and remission rates of 25–29%.”
Dutton, M., Schwenn, P., Mitchell, J., Hoffmann, P., Bailey, N. W., Fitzgerald, P. B., Lagopoulos, J., & Can, A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251398677 · Cited by 2
“Psilocybin has also shown promise in phase 2 trials (Carhart-Harris et al., 2021; Kittur et al., 2025; Raison et al., 2023).”
Mehmood, M., Bremler, R., Spriggs, M. J., Kettner, H., Roseman, L., Damgaard, L., Carhart-Harris, R. L., Erritzøe, D., & Zeifman, R. J. (2025) · Psychedelic Medicine · doi:10.1177/28314425251392251 · Cited by 4
“12 23 A study conducted by Carhart-Harris et al. 14 found that, relative to escitalopram, psilocybin therapy led to greater improvements in anxiety, well-being, and experiential avoidance, symptoms often elevated among individuals with ACEs.”
Self-citationSuggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy
Lappan, S. N., & Davis, S. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251404021 · Cited by 2
“39 Nondirective guidance An approach grounded in early psychedelic traditions, where facilitators provide emotional presence without interpretation or suggestion.”
Participant Experiences of Therapeutic Touch in Psilocybin‐Assisted Therapy
Ham, R., Gardner, J., Carter, A., & Liknaitzky, P. (2026) · Brain and Behavior · doi:10.1002/brb3.71262 · Cited by 3
“Psychedelic-assisted therapy (PAT) is emerging as a promising mental health intervention (Bahji et al. 2020 ; Carhart-Harris et al. 2021 ; Garcia-Romeu et al. 2014 ; Goldberg et al. 2020 ; Griffiths 2016 ; Moreno et al. 2006 ).”
Psychedelic-assisted psychotherapy: Clarifying the role of the "psychotherapy"
Jerotić, S., Čolović, O., & Marić, N. P. (2026) · Medicinska istrazivanja · doi:10.5937/medi0-62051 · Cited by 2
Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies
Farré‐Colomés, À., Rublinetska, O., & Soto-Angona, Ó. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00384-w · Cited by 3
Hashimoto, K., Arıcıoğlu, F., & Çetin, M. (2026) · Psychiatry and Clinical Psychopharmacology · doi:10.65801/pcp.3512 · Cited by 2
“A head-to-head comparison with escitalopram suggested comparable or greater reductions in depressive symptoms with psilocybin; however, methodological differences and challenges in maintaining blinding limit definitive conclusions 34 .”
Ekins, T. G., Deng, T., & Ahmed, O. J. (2026) · Brain and Behavior · doi:10.1002/brb3.71406 · Cited by 2
“…medicine has shown great promise for treating neuropsychiatric disorders (Johnson et al. 2014 , 2017 ; Bogenschutz et al. 2015 ; R. L. Carhart-Harris et al. 2016 , 2017 , 2018 ; R. Carhart-Harris et al. 2021 ; Sanches et al. 2016 ; Daws et al. 2022 ; Goodwin et al. 2022 ; Zaretsky et al. 2024 ).”
Avram, M., Menegaux, A., Müller, F., Zaczek, H., Korda, A. I., Rogg, H. V., Becker, A. M., Ley, L., Liechti, M. E., & Borgwardt, S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102791 · Cited by 2
Hood, A., & Elkins, G. R. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00507 · Cited by 2
Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives
Kervadec, E., Bezo, A., Serreau, R., Strika-Bruneau, L., Fauvel, B., Amirouche, A., Benyamina, A., & Roméo, B. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002197 · Cited by 3
Boehnke, K. F., Pouyan, N., & Aday, J. S. (2026) · Drugs · doi:10.1007/s40265-026-02339-5 · Cited by 2
“There are several Phase II studies showing benefits of psilocybin-assisted therapy for depressive disorders [60, 62, 157], with Phase III trials currently ongoing.”
Allen, J., Jupp, B., Baker, T. L., Haskali, M. B., Brkljača, R., Plummer, Z., Sun, M., Brand, J., Christie, B. R., Debert, C. T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102867 · Cited by 2
Roles and therapeutic prospects of the laminin family in disorders of the nervous system
Zhang, X., Li, X., Gao, L., Qiao, Y., Lv, B., Zhang, Q. D., Zhang, M., Yu, J., Li, H., Bi, H., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08410-9 · Cited by 2
“…outcomes remain to be established) [363]; the neurosteroid-targeting oral agent zuranolone has been approved for postpartum depression [364]; psychedel-ics (e.g., psilocybin) show dose-related short-term benefits in phase II trials of treatment-resistant depression but remain investigational [365].”
From trial to clinic: psilocybin’s efficacy in routine treatment-resistant depression
Martiadis, V. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101780 · Cited by 2
(2021) · Revista de Psiquiatría del uruguay · doi:10.46706/psi/85.1.4 · Cited by 8
Top studies of 2021 relevant to primary care: From the PEER team
Moe, S. S., Perry, D., Thomas, B., Nickonchuk, T., Braschi, É., Dugré, N., Finley, C. R., Lindblad, A. J., Potter, J., & Allan, G. M. (2022) · Canadian Family Physician · doi:10.46747/cfp.6805329 · Cited by 2
A long trip into the universe: Psychedelics and space travel
Lerer, L. B., & Varia, J. C. (2022) · Frontiers in Space Technologies · doi:10.3389/frspt.2022.899159 · Cited by 2
“We recognize that there are still substantial gaps in the biomedical science supporting the generalized preventive and therapeutic application of psychedelics, while noting that psilocybin (for depression) and MDMA (for PTSD) are in advanced clinical development with potential FDA approvals from 2024, and that ketamin…”
BackgroundVideira, N. B., Nair, V., Paquet, V., & Calhoun, D. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4533 · Cited by 2
Psilocibina e sua perspectiva no tratamento do transtorno depressivo maior: uma revisão integrativa
Costa, J. C. G. D., Borba, E. R. D. C., & Vilanova, C. M. (2023) · Conexão Ciência (Online) · doi:10.24862/cco.v18i2.1750 · Cited by 9
Bis(4-acetoxy- N -ethyl- N - n -propyltryptammonium) fumarate–fumaric acid (1/1)
Pham, D. N. K., Sackett, N. B., Chadeayne, A. R., Golen, J. A., & Manke, D. R. (2023) · IUCrData · doi:10.1107/s2414314623007794 · Cited by 2
Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?
Chupin, J., López‐Castromán, J., Brière, C., Pereira, F., Hingray, C., & Conejero, I. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111163 · Cited by 2
Kratina, S., & Mayo, L. M. (2023) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2246637 · Cited by 2
Psilocybin in Bipolar II Study Provides Preliminary Data on Safety
Yaden, D. B., Gukasyan, N., & Nayak, S. M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4680 · Cited by 2
Uso da psilocibina no tratamento de transtornos psiquiátricos: Revisão da literatura
Teixeira, G. B., Passos, A. C. D. B., Farias, B. V., Girão, A. B. C. F., Marçal, L. D. S., Albuquerque, K. O. D. S., & Ferreira, M. A. D. (2024) · Research Society and Development · doi:10.33448/rsd-v13i2.44971 · Cited by 4
Cognición extendida y símbolos de la velada mazateca con hongos psilocibios
Caynas-Rojas, S., & Mercadillo, R. E. (2024) · Andamios · doi:10.29092/uacm.v21i54.1063 · Cited by 2
Aghaei, A. M., Weleff, J., Martins, B. S., Ing, K., Fontenele, R., Barnett, B. S., Anand, A., & Nia, A. B. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00574-y · Cited by 2
“Contemporary psychedelic research has not incorporated psychotherapy for most ketamine treatment trials [15], while psilocybin clinical trials have primarily adhered to the “psychedelic psychotherapy” model [12, 16–20].”
Dost, D., Benyamina, A., & Karila, L. (2024) · L Encéphale · doi:10.1016/j.encep.2024.02.007 · Cited by 2
The influence of psilocybin on subconscious and conscious emotional learning
Casanova, A. F., Ort, A., Smallridge, J. W., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2024) · iScience · doi:10.1016/j.isci.2024.110034 · Cited by 4
“8 Psilocybin and lysergic acid di-ethylamide (LSD) have been shown to significantly reduce symptoms of depression and anxiety in patients with major depressive disorder (MDD), 9–12 anxiety, 13 and substance use disorder.”
BackgroundPsilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study
Peck, S. K., Shao, S., Gruen, T., Yang, K. H., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022013 · Cited by 5
Baraghithy, S., Gammal, A., Permyakova, A., Hamad, S., Kočvarová, R., Calles, Y., & Tam, J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00353 · Cited by 2
Fluyau, D., Kailasam, V. K., & Revadigar, N. (2024) · Psychoactives · doi:10.3390/psychoactives3040029 · Cited by 2
Li, J.-R., Chiang, K.-T., Kao, Y., Yu, C., Yang, F., Liang, C., & Hsu, T. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.016 · Cited by 4
Martire, G., Sipple, D., Baron, D. A., Gold, M. S., Lewandowski, K.-U., Dennen, C. A., Sharafshah, A., Elman, I., Thanos, P. K., Modestino, E. J., et al. (2024) · PubMed · Cited by 2
Fernandes-Nascimento, M. H., Viana-Ferreira, K., & Negrão, A. B. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0031 · Cited by 3
“6 This reorganization may establish new pathways of brain communication, enhancing emotional processing in individuals with mental disorders, a hypothesis supported by studies from Carhart-Harris et al. (2012, 2016, 2018) 8,9,11 and Rucker et al. (2022).”
O'Connor, S., Godfrey, K., Reed, S., Peill, J. M., Rohani-Shukla, C., Healy, M. P., Robbins, T. W., de Souza, A. M. F. L. P., Tyacke, R. J., Papasyrou, M., et al. (2025) · Cureus · doi:10.7759/cureus.78171 · Cited by 5
“Most studies assessing psilocybin in the context of mental health have explored 25 mg doses [48,58].”
Self-citationAkzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländern
Hartter, N., Däumichen, M., Schmidt, C., Wolff, M., Gründer, G., & Jungaberle, H. (2025) · Der Nervenarzt · doi:10.1007/s00115-024-01792-5 · Cited by 3
Public priorities in psychedelics research
Bălăeţ, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00362 · Cited by 2
Halperin, D., On, T. B., Tadmor, N., Simon, A. M., Cherniak, A. D., & Simon, G. (2025) · Future Humanities · doi:10.1002/fhu2.70009 · Cited by 2
“Negative psychedelic experiences may be followed by months or even years of emotional distress (Carhart ‐ Harris et al. 2021; Evans et al. 2023; Goodwin et al. 2022; Johnstad 2021).”
Miller, C. W. T., & Kozak, Z. (2025) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000425 · Cited by 2
Is there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 4
Chisamore, N., Kaczmarek, E. S., Doyle, Z., Johnson, D. E., Weiglein, G., Meshkat, S., Brudner, R. M., Blainey, M. G., Riva-Cambrin, J., McIntyre, R. S., et al. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251328316 · Cited by 2
The Ethics of Set and Setting in Psychedelic Psychotherapy
Patch, K., & Smith, W. (2025) · Neuroethics · doi:10.1007/s12152-025-09600-w · Cited by 2
Estimating heterogeneity of treatment effect in psychiatric clinical trials
Siegel, J. S., Zhong, J., Tomioka, S., Ogirala, A., Faraone, S. V., Szabo, S. T., Koblan, K. S., & Hopkins, S. C. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.09.070 · Cited by 2
Hoffman, K. A., Korthuis, T., Pertl, K., & Morgan, D. J. (2025) · International Journal of Multiple Research Approaches · doi:10.29034/ijmra.v17n1a1 · Cited by 2
Beerens, S., Winterer, J., Lukacsovich, D., Földy, C., & Wozny, C. (2022) · eNeuro · doi:10.1523/eneuro.0005-22.2022 · Cited by 2
“Antidepressant effects of psychedelics, such as psilocybin, are believed to manifest themselves through acting on 5HT2aRs (for review, see Nutt et al., 2020; Carhart-Harris et al., 2021).”
BackgroundWillingness to participate in entheogen use research in naturalistic settings
Kirk, R. D., Uhley, O. M., Lehfeldt, P., Shields, C. M., Garretson, M., Collins, A., Wahbeh, H., & Dahmer, S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00238 · Cited by 3
Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics
Ibi, D. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22141 · Cited by 2
Psychedelic Experiences and the Enactive Approach
Meling, D., & Scheidegger, M. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192844064.013.9 · Cited by 3
Synaptic plasticity in fronto-insular circuits underlying stress susceptibility and resilience
Rocks, D., & Liston, C. M. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.12.006 · Cited by 2
Rapid quantification of Psilocybin with reversed-phase HPLC and single-wavelength detectionPreprint
Samuelsson, A., Janusson, E., Shah, S., & Roggen, M. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-70mm1 · Cited by 2
Husain, M. I., Umer, M., & Mulsant, B. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2063274 · Cited by 2
“59 patients with moderate-to-severe MDD, comparing psilocybin-assisted psychotherapy with escitalopram [12].”
BackgroundSchatzberg, A. F. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220812 · Cited by 2
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
Lutyens, D. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.21904854 · Cited by 3
Finkelstein, C., Soha, O., Roy, A., Phillipou, A., & Rossell, S. L. (2023) · Research Square · doi:10.21203/rs.3.rs-3189970/v1 · Cited by 3
Peled‐Avron, L., Aday, J. S., Kalafateli, A. L., Hamilton, H., & Woolley, J. D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1431389 · Cited by 2
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment
Somers, M., & Scheepers, F. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240121 · Cited by 2
Mennenga, S. E., Hanson, T., Semple, M. G., Lifshitz, D., Flores, B., Balducci, J., Harker, S. A., Ford, A., & Lewis, C. R. (2025) · Research Square · doi:10.21203/rs.3.rs-7890051/v1 · Cited by 2
Complexity as a Potential Neurophysiological Correlate of AwePreprint
Chen, J. C. C., Mace, G., Ostrand, A. E., Valtierra, C., Griffith, S., Campusano, R., Li, A. I., Vinson, E., Schlomberg, J. T., Eshel, M. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.20.689403 · Cited by 2
Self-citation
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.